Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer

医学 奥沙利铂 全直肠系膜切除术 结直肠癌 放化疗 内科学 新辅助治疗 人口 诱导化疗 氟尿嘧啶 化疗 随机对照试验 外科 肿瘤科 癌症 乳腺癌 环境卫生
作者
Emmanouil Fokas,Anke Schlenska‐Lange,Bülent Polat,Günther Klautke,Gerhard G. Grabenbauer,Rainer Fietkau,Thomas Kuhnt,Ludger Staib,Thomas Baptist Brunner,Anca‐Ligia Grosu,Simon Kirste,Lutz Jacobasch,Michael Allgäuer,Michael P. Flentje,Christoph‐Thomas Germer,Robert Grützmann,Guido Hildebrandt,Matthias Schwarzbach,Wolf O. Bechstein,Heiko Sülberg
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:8 (1): e215445-e215445 被引量:382
标识
DOI:10.1001/jamaoncol.2021.5445
摘要

IMPORTANCE: Total neoadjuvant therapy has been increasingly adopted for multimodal rectal cancer treatment. The optimal sequence of chemoradiotherapy (CRT) and chemotherapy needs to be established. OBJECTIVE: To report the long-term results of the secondary end points prespecified in the Randomized Phase 2 Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy (CAO/ARO/AIO-12 trial) for Locally Advanced Rectal Cancer. DESIGN, SETTING, AND PARTICIPANTS: This secondary analysis of a randomized clinical trial included 311 patients who were recruited from the accrued CAO/ARO/AIO-12 trial population from June 15, 2015, to January 31, 2018, from 18 centers in Germany. Patients with cT3-4 and/or node-positive rectal adenocarcinoma were included in the analysis. Data were analyzed from June 15, 2015, to January 31, 2018. The follow-up analysis was conducted between January 31, 2018, and November 30, 2020. INTERVENTIONS: Patients were randomly assigned to group A for 3 cycles of fluorouracil, leucovorin, and oxaliplatin before fluorouracil/oxaliplatin CRT (50.4 Gy), or to group B for CRT before chemotherapy. Total mesorectal excision was scheduled on day 123 after the start of total neoadjuvant therapy in both groups. MAIN OUTCOMES AND MEASURES: The end points assessed in this secondary analysis included long-term oncologic outcomes, chronic toxicity, patient-reported outcome measures for global health status (GHS) and quality of life (QoL), and the Wexner stool incontinence score. RESULTS: Of the 311 patients enrolled, 306 were evaluable, including 156 in group A (mean [SD] age, 60 [11] years; 106 men [68%]) and 150 in group B (mean [SD] age, 62 [10] years; 100 men [67%]). After a median follow-up of 43 months (range, 35-60 months), the 3-year disease-free survival was 73% in both groups (hazard ratio, 0.95; 95% CI, 0.63-1.45, P = .82); the 3-year cumulative incidence of locoregional recurrence (6% vs 5%, P = .67) and distant metastases (18% vs 16%, P = .52) were not significantly different. Chronic toxicity grade 3 to 4 occurred in 10 of 85 patients (11.8%) in group A and 8 of 66 patients (9.9%) in group B at 3 years. The GHS/QoL score decreased after total mesorectal excision but returned to pretreatment levels 1 year after randomization with no difference between the groups. Stool incontinence deteriorated 1 year after randomization in both groups and only improved slightly at 3 years, but never reached baseline levels. CONCLUSIONS AND RELEVANCE: This secondary analysis of a randomized clinical trial showed that CRT followed by chemotherapy resulted in higher pathological complete response without compromising disease-free survival, toxicity, QoL, or stool incontinence and is thus proposed as the preferred total neoadjuvant therapy sequence if organ preservation is a priority. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02363374.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
Jasper的应助被wangbaoshan采纳,获得10
1秒前
ZWQ发布了新的文献求助10
1秒前
1秒前
1秒前
祈兰完成签到 ,获得积分10
1秒前
yyryyrr发布了新的文献求助10
1秒前
勤恳易真发布了新的文献求助10
1秒前
元柏完成签到,获得积分10
2秒前
Nighttt完成签到,获得积分10
2秒前
le完成签到,获得积分20
2秒前
CK完成签到,获得积分10
2秒前
menghan发布了新的文献求助10
2秒前
耳喃完成签到,获得积分10
3秒前
Owen的应助被ee采纳,获得10
3秒前
完美世界的应助被nnn采纳,获得10
3秒前
高贵碧凡发布了新的文献求助10
3秒前
科研怪完成签到 ,获得积分10
3秒前
欣慰的冰旋完成签到 ,获得积分10
4秒前
隐形曼青的应助被你好采纳,获得10
4秒前
米朗心完成签到,获得积分10
4秒前
酷波er的应助被KK采纳,获得10
4秒前
4秒前
沙力VAN发布了新的文献求助10
4秒前
嘭嘭嘭发布了新的文献求助20
5秒前
33Rylee发布了新的文献求助10
5秒前
科研通AI6.2的应助被SZW采纳,获得10
5秒前
5秒前
百甲发布了新的文献求助10
5秒前
5秒前
科目三的应助被愤怒的之玉采纳,获得10
5秒前
打打的应助被yyw19930920采纳,获得10
5秒前
无花果的应助被还原糖采纳,获得10
5秒前
cole完成签到,获得积分10
5秒前
1111的应助被侯侯采纳,获得50
5秒前
专注的箴完成签到,获得积分10
6秒前
7秒前
7秒前
7秒前
SciGPT的应助被于海采纳,获得10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Markov Decision Processes and Reinforcement Learning 700
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8169168
求助须知:如何正确求助?哪些是违规求助? 9562182
关于积分的说明 21764903
捐赠科研通 7760775
什么是DOI,文献DOI怎么找? 3430228
关于科研通互助平台的介绍 2554080
邀请新用户注册赠送积分活动 2474932